Arovella Therapeutics Limited (AU:ALA) has released an update.
Arovella Therapeutics Ltd, known for its innovative iNKT cell therapy platform, has announced an investor webinar to discuss recent advancements and future plans following a successful pre-IND meeting with the FDA. The webinar, led by CEO Dr. Michael Baker, will provide insights into the company’s next steps for ALA-101 and its potential in treating CD19-positive blood cancers. Interested parties can join the webinar on Wednesday, 18 September 2024, and access the recording afterward on the company’s website and social channels.
For further insights into AU:ALA stock, check out TipRanks’ Stock Analysis page.
